SCHEMBL22130657

SCHEMBL22130657

O=C1C=Cc2c(ccn2S(=O)(=O)c2ccccc2)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL1 Q15717 4/20 0.57
HTR6 P50406 10/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
MET P08581 1/20 0.41
CYP2C19 P33261 1/20 0.41
MMP2 P08253 1/20 0.39
PARL Q9H300 1/20 0.39
POLB P06746 2/20 0.38
KDM4E B2RXH2 1/20 0.38
BCHE P06276 1/20 0.38
PTPRC P08575 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130656 0.76 ELAVL1 (0.49) ELAVL1HTR6MEN1ALDH1A1LMNA
SCHEMBL19737490 0.73 ELAVL1 (1.00) ELAVL1HTR6MEN1ALDH1A1LMNA
SCHEMBL22130655 0.71 ELAVL1 (0.68) ELAVL1HTR6MEN1ALDH1A1LMNA
Dimethylamine SCHEMBL21222569 0.69 ELAVL1 (0.90) ELAVL1HTR6HPGDPARLL3MBTL1
SCHEMBL22130714 0.68 ELAVL1 (0.83) ELAVL1HTR6MEN1LMNAHPGD
SCHEMBL24282440 0.68 PARL (0.50) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL1266100 0.66 PARL (0.47) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL21222486 0.65 ELAVL1 (1.00) ELAVL1HTR6LMNAHTTKDM4E
SCHEMBL22130634 0.65 ELAVL1 (0.83) ELAVL1HTR6ALDH1A1MMP2L3MBTL1
SCHEMBL28195727 0.64 HTR6 (0.52) ELAVL1HTR6MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885HTR6 1922/4885MEN1 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.